Skip Navigation



JAC Advance Access published online on September 30, 2003
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkg443
© 2003 by The British Society for Antimicrobial Chemotherapy
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
52/5/853    most recent
dkg443v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Stallmann, H. P.
Right arrow Articles by Wuisman, P. I. J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stallmann, H. P.
Right arrow Articles by Wuisman, P. I. J. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2003 The British Society for Antimicrobial Chemotherapy

Brief report

Continuous-release or burst-release of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11) from calcium phosphate bone substitutes

Hein P. Stallmann 1 , Christopher Faber 1 , Eveline T. Slotema 2 , D. M. Lyaruu 3 , Antonius L. J. J. Bronckers 3 , Arie V. Nieuw Amerongen 4 , and Paul I. J. M. Wuisman 2 *

1 Departments of Orthopaedic Surgery/VU University Medical Center, PO Box 7057, and Oral Cell Biology/ACTA, 1007 MB Amsterdam, The Netherlands
2 Orthopaedic Surgery/VU University Medical Center, PO Box 7057
3 Oral Cell Biology/ACTA, 1007 MB Amsterdam, The Netherlands
4 Oral Biochemistry/ACTA, 1007 MB Amsterdam, The Netherlands

* Corresponding author. E-mail: orthop{at}vumc.nl.

Received 11 February 2003 ; revised 13 August 2003 ; accepted 13 August 2003

Abstract

Objectives: In order to identify possible drug delivery systems against resistant bone infection, we determined the release of the antimicrobial peptide (AMP) human lactoferrin 1-11 (hLF1-11) from commercially available bone substitutes.

Methods: We combined six calcium phosphate cements and six granule-types with 5 mg/g hLF1-11 and measured its availability and release in vitro from cements (7 days) and granules (3 days). The integrity and antimicrobial activity of the hLF1-11 that was released during the first 24 h were measured, using mass spectrometry, and a killing assay on methicillin-resistant Staphylococcus aureus (MRSA).

Results: Most of the cements showed burst release followed by low-level continuous release, whereas the coated granules showed high burst release for 24 h. After release the peptide was active (in nine of 12 materials) and intact.

Conclusions: Different release profiles may be obtained by choosing the appropriate carrier, which supports the feasibility of biodegradable carriers releasing AMPs against resistant infections.

Keywords: bone infections, human lactoferrin, biodegradable, carriers
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
C. Faber, H. P. Stallmann, D. M. Lyaruu, U. Joosten, C. von Eiff, A. van Nieuw Amerongen, and P. I. J. M. Wuisman
Comparable Efficacies of the Antimicrobial Peptide Human Lactoferrin 1-11 and Gentamicin in a Chronic Methicillin-Resistant Staphylococcus aureus Osteomyelitis Model
Antimicrob. Agents Chemother., June 1, 2005; 49(6): 2438 - 2444.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
H. P. Stallmann, C. Faber, A. L. J. J. Bronckers, A. V. Nieuw Amerongen, and P. I. J. M. Wuisman
Osteomyelitis prevention in rabbits using antimicrobial peptide hLF1-11- or gentamicin-containing calcium phosphate cement
J. Antimicrob. Chemother., August 1, 2004; 54(2): 472 - 476.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.